Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Weight-Loss drug cagrilintide shows promise in Late-Stage trial

NCT ID NCT07220642

Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 4 times

Summary

This Phase 3 trial tests whether cagrilintide, a new injectable drug, helps people with overweight or obesity lose weight. About 300 adults will receive either cagrilintide or a placebo for up to 18 months, along with lifestyle counseling. The study measures weight change and waist size reduction.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
cagrilintide
What this could lead to
If successful, cagrilintide could become a new weight-loss medication for people with overweight or obesity.
What could go wrong
This is a Phase 3 trial, but results may not match real-world use. Side effects are possible, and not everyone may lose significant weight.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study * Female or male (sex at birth) * Age 18 years or above at the time of signing the informed consent * History of at least one self-reported unsuccessful dietary effort to lose body weight (a\*) * Body mass index (BMI) greater than or equal to \>= 30.0 kilogram per square meter (kg/m\^2), or BMI greater than or equal to \>= 27.0 kg/m\^2 with the presence of at least one weight related comorbidity including, but not limited to, hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease (a\*) Exclusion criteria: * History of type 1 or type 2 diabetes (a\*) * Treatment, or intention to initiate treatment, with any medication prescribed for the indication of weight management within 180 days before screening (a\*) * Previous dosing of marketed or non-marketed amylin-based compounds (a\*) (a\*) - As declared by the participant, reported in the medical records or at the investigator's discretion.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity Overweight

Contacts and locations

Locations

  • A.O.U. Bologna_ Policlinico S.Orsola Malpighi

    Bologna, 40138, Italy

  • AOUP Giaccone Palermo

    Palermo, Sicily, 90127, Italy

  • Brunel Medical Practice

    Torquay, Devon, TQ1 4QX, United Kingdom

  • CEDIC Centro de Investigación Clínica

    CABA, C1060ABA, Argentina

  • CIPREC Pueyrredon

    Buenos Aires, C1119ACN, Argentina

  • Care Clinic Sp. z o. o.

    Katowice, 40-568, Poland

  • Centre Hospitalier Universitaire de Nantes-Hopital Nord Laennec

    Saint-Herblain, 44800, France

  • Centre de Recherche Clinique Portes Du Sud

    Vénissieux, 69200, France

  • Centricity Research Mirabel

    Mirabel, Quebec, J7J 2K8, Canada

  • Centricity Research Oshawa

    Oshawa, Ontario, L1J 2K9, Canada

  • Centricity Research Toronto

    Toronto, Ontario, M4G 3E8, Canada

  • Diablo Clinical Research, Inc.

    Walnut Creek, California, 94598, United States

  • Drammen sykehus - Vestre Viken HF

    Drammen, 3004, Norway

  • Florida Inst For Clin Res LLC

    Orlando, Florida, 32825, United States

  • Fondazione Policlinico Universitario Agostino Gemelli IRCS

    Rome, RM, 00168, Italy

  • G.A. Research Associates Ltd.

    Moncton, New Brunswick, E1G 1A7, Canada

  • Hamilton Medical Research Group

    Hamilton, Ontario, L8L 5G4, Canada

  • Haukeland Universitetssykehus

    Bergen, 5021, Norway

  • Hunter Diabetes Centre

    Merewether, New South Wales, 2291, Australia

  • IRCCS Ospedale San Raffaele Milano

    Milan, 20132, Italy

  • InnoDiab Forschung GmbH

    Essen, 45136, Germany

  • Midwest Inst For Clin Res

    Indianapolis, Indiana, 46260, United States

  • Milestone Research

    London, Ontario, N5W 6A2, Canada

  • NBR Polska Tomasz Klodawski

    Warsaw, 00-710, Poland

  • North Coast Medical Ltd

    Newquay, Cornwall, TR7 1RU, United Kingdom

  • Nova Scotia Hlth Halifax

    Halifax, Nova Scotia, B3H 1V7, Canada

  • Oak Tree Surgery

    Liskeard, Cornwall, PL14 3XA, United Kingdom

  • Osteo-Medic s.c. A. Racewicz, J. Supronik

    Bialystok, 15-351, Poland

  • Oviedo Medical Research, LLC

    Oviedo, Florida, 32765, United States

  • PharmQuest Life Sciences LLC

    Greensboro, North Carolina, 27408, United States

  • RED-Institut für medizinische Forschung und Fortbildung GmbH

    Oldenburg in Holstein, 23758, Germany

  • Selma Medical Associates

    Winchester, Virginia, 22601-3834, United States

  • St. Olavs Hospital HF_Endokrinologisk avdeling

    Trondheim, NO-7030, Norway

  • StudyMetrix Research LLC

    City of Saint Peters, Missouri, 63303, United States

  • Sydney Cardiometabolic Centre

    Liverpool, New South Wales, 2170, Australia

  • Terpa Sp. z o.o. Sp. k.

    Lublin, 20-333, Poland

  • Univ of Colorado at Denver

    Aurora, Colorado, 80045, United States

  • Walgreens - Store 11760

    Oak Park, Illinois, 60302, United States

  • Wendisch - Dahl Hamburg - DZHW

    Hamburg, 22607, Germany

  • Wharton Medical Clinic Clinical Trials (Hamilton)

    Hamilton, Ontario, L8L 5G8, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.